Round two: Window opens for Pfizer move on AstraZeneca as three-month waiting period ends
US drugs giant Pfizer can today renew its ambitions to buy AstraZeneca in a £69billion mega-deal.
The Viagra-maker is looking for a way to slash its global tax bill by shifting its tax base out of the US. Its initial attempts to buy Astra, Britain’s second biggest pharmaceuticals group, failed earlier in the summer.
But today a three-month waiting period ends, allowing the group to have another stab at the deal. Under UK takeover rules, Pfizer can make one take-it-or-leave-it offer in private to Astra’s board.
A second takeover attempt? Astra boss Pascal Soriot warned MPs the deal would cost lives, as Astra's development of cancer drugs would be stalled by the process of integrating the two firms
The British firm is also allowed to invite Pfizer back to the negotiating table. But Pfizer is not allowed to re-enter formal negotiations with Astra until November – a full six months after the original deal collapsed.
Shares in Astra climbed 8 per cent last week to finish at 4418p – although this is still a long way below the £55 that Pfizer offered. Astra’s board previously said it would consider a bid of £58.50.
Analysts still believe the deal may be resurrected, because the US group’s desire to slash its tax bill is so strong. Pfizer boss Ian Read previously said that he was ‘aggressively’ eyeing takeover possibilities. But the Astra takeover met with ferocious opposition from both sides of the Atlantic.
In the UK, Astra boss Pascal Soriot warned MPs the deal would cost lives, as Astra’s development of cancer drugs would be stalled by the process of integrating the two firms.
The Frenchman has said the company has a strong future as an independent, and has laid out a plan for reviving its fortunes.
Pfizer’s overtures also faced huge political opposition, with Labour threatening to bring in a ‘public interest’ test for overseas takeovers if the party wins power in the general election in May.
Because a prospective deal is likely to take many months to complete given the large number of countries that would have to give regulatory clearance, Pfizer is likely to be keen to push ahead sooner rather than later.
The prospect of a multi-billion pound tax saving is still the main driver for the Astra deal, sources have said. In the US the issue of tax inversions, where firms move their tax headquarters out of the US to avoid its 35 per cent tax rates, have become a fiercely political issue.
President Obama has called companies that engage in tax inversions ‘corporate deserters’ and senior Democrats are moving to close tax loopholes as soon as possible.
Dealmakers estimate that there are between 20 and 25 US firms desperately seeking to carry out tax inversions before the window closes.
Already AbbVie has bought Shire, an Irish-based drugs group, in a £31billion deal that slashed the US group’s tax bill by 40 per cent. But a backlash against US groups that do this has already begun.
Walgreens, which is buying Boots in a £5billion deal, has said it will not invert its tax base in order to avoid facing a consumer boycott in the US, where it is the largest owner of beauty and drugs stores. Astra and Pfizer both refused to comment.
Most watched Money videos
- How to invest for income and growth: SAINTS' James Dow
- Inside the new Ferrari V12 Cilindri
- Land Rover unveil newest all-electric Range Rover SUV
- 2025 Aston Martin DBX707: More luxury but comes with a higher price
- BMW's Vision Neue Klasse X unveils its sports activity vehicle future
- MailOnline asks Lexie Limitless 5 quick fire EV road trip questions
- Skoda reveals Skoda Epiq as part of an all-electric car portfolio
- Tesla unveils new Model 3 Performance - it's the fastest ever!
- Mini celebrates the release of brand new all-electric car Mini Aceman
- Mini Cooper SE: The British icon gets an all-electric makeover
- Blue Whale fund manager on the best of the Magnificent 7
- 'Now even better': Nissan Qashqai gets a facelift for 2024 version
- MIDAS SHARE TIPS UPDATE: Wind is turning in Octopus...
- British businesses awash with 'accidental' bosses who...
- CITY WHISPERS: Bill Ackman's cerulean eyes charm...
- Shipping broker Clarksons on list of shame after...
- Cost-of-living crunch wipes shine off Thomas Sabo jewellery
- TONY HETHERINGTON: Boss behind firms fined £340k for over...
- A good week - not before time, but let's not get carried...
- Hollywood silly money? I'd only have stuffed it under the...
- As world lurches from crisis to crisis, experts share...
- 86-year-old Peter's woes with a faulty smart meter that...
- Virgin Money's biggest independent investor...
- Britain's nascent battery industry receives shot in the...
- Helium and hydrogen company set to join stock market in...
- Where is Labour's 'white heat' revolution to revive...
- JOHCM UK EQUITY INCOME FUND: Rate cuts... and a spending...
- North Sea projects worth £21bn put at risk by Labour: Tax...
- MIDAS SHARE TIPS: Why it soon won't be hip to give the...
- Ikea pushes back opening of its Oxford Street store to...